X4 Pharmaceuticals Inc
XFOR
Get informed when a big investor buys or sells
+ FollowMarket Cap$330.12M
Close$
$2.71
22.6% downside
Current Fair Value
22.6% downsideOvervalued by 22.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $330.12 Million |
|---|---|
| Enterprise Value | $136.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.87 |
| Beta | 0.35 |
| Outstanding Shares | 126,344,020 |
Return
| Return on Equity | -57.98% |
|---|---|
| Return on Assets | -35.62% |
| Return on Invested Capital | -42.95% |
Valuation & Multiples
| P/E Ratio | -2.92 |
|---|---|
| PEG | 7.83 |
| Price to Sales | - |
| Price to Book Ratio | 3.5 |
| Enterprise Value to Revenue | 8.6 |
| Enterprise Value to EBIT | -1.36 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$2.42 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$2.26 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 500,300▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.13%▲ 4.52% |
|---|---|
| Total Invested | $449.17M▲ 20.18% |
| Investors Holding | 91▲ 10.00% |
ESG Score
No data
About X4 Pharmaceuticals Inc
72 employeesX4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare di...